Sun Yat-sen University

About: Sun Yat-sen University is a education organization based out in Guangzhou, Guangdong, China. It is known for research contribution in the topics: Population & Cancer. The organization has 115149 authors who have published 113763 publications receiving 2286465 citations. The organization is also known as: Zhongshan University & SYSU.

Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3

Abstract: Zi-Jiang Chen and Yongyong Shi report a genome-wide association study for polycystic ovary syndrome, a common metabolic and endocrine disorder in women. They identified three susceptibility loci associated with this condition.

Underexposed Photo Enhancement Using Deep Illumination Estimation

Abstract: This paper presents a new neural network for enhancing underexposed photos. Instead of directly learning an image-to-image mapping as previous work, we introduce intermediate illumination in our network to associate the input with expected enhancement result, which augments the network's capability to learn complex photographic adjustment from expert-retouched input/output image pairs. Based on this model, we formulate a loss function that adopts constraints and priors on the illumination, prepare a new dataset of 3,000 underexposed image pairs, and train the network to effectively learn a rich variety of adjustment for diverse lighting conditions. By these means, our network is able to recover clear details, distinct contrast, and natural color in the enhancement results. We perform extensive experiments on the benchmark MIT-Adobe FiveK dataset and our new dataset, and show that our network is effective to deal with previously challenging images.

Supramolecular isomerism in coordination polymers.

Abstract: Coordination polymers have been emerging as a topical research field in crystal engineering, solid-state chemistry, and materials science. Considering the wide occurrence of structural and compositional diversity during self-assembly and crystallization, supramolecular isomerism represents an indication of composition control and structure prediction. Actually, supramolecular isomerism is not just an obstacle or challenge, but also a good opportunity for developing novel materials and a better understanding of self-assembly and crystal growth. This critical review provides an overview of the developing knowledge, in the context of supramolecular isomerism, of the design, synthesis, and properties of coordination polymers (97 references).

Novel cold cathode materials and applications

Abstract: Field emission (FE) is based on the physical phenomenon of quantum tunneling, in which electrons are injected from the surface of materials into vacuum under the influence of an applied electric field. A variety of field emission cold cathode materials have been developed to date. In this review, we shall focus on several kinds of novel cold cathode materials that have been developed in the past decade. These include materials for microfabricated field-emitter arrays, diamond and related films, carbon nanotubes, other quasi one-dimensional nanomaterials and printable composite materials. In addition, cold cathode materials have a wide range of applications such as in flat panel displays, high-power vacuum electronic devices, microwave-generation devices, vacuum microelectronic devices and vacuum nanoelectronic devices. Applications are in consumer goods, military industries and also space technology. A comprehensive overview of the various applications is presented. Recently, recognizing the strong possibility that vacuum nanoelectronic devices using quasi one-dimensional nanomaterials, such as carbon nanotubes may emit electrons with driving voltages comparable to that of a solid-state device, there is a growing interest in novel applications of such devices. With such exciting opportunities, there is now a flurry of activities to explore applications far beyond those considered for the conventional hot cathodes that operate on thermionic emission. We shall discuss the details of a number of fascinating potential applications.

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Abstract: Summary Background In the international randomised phase 3 CORRECT trial (NCT01103323), regorafenib significantly improved overall survival versus placebo in patients with treatment-refractory metastatic colorectal cancer. Of the 760 patients in CORRECT, 111 were Asian (mostly Japanese). This phase 3 trial was done to assess regorafenib in a broader population of Asian patients with refractory metastatic colorectal cancer than was studied in CORRECT. Methods In this randomised, double-blind, placebo-controlled, parallel-group, phase 3 trial done in 25 hospitals in mainland China, Hong Kong, South Korea, Taiwan, and Vietnam, we recruited Asian patients aged 18 years or older with progressive metastatic colorectal cancer who had received at least two previous treatment lines or were unable to tolerate standard treatments. Patients had to have an Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of at least 3 months, and adequate bone marrow, liver, and renal function, without other uncontrolled medical disorders. We randomly allocated patients (2:1; with a computer-generated unicentric randomisation list [prepared by the study funder] and interactive voice response system; block size of six; stratified by metastatic site [single vs multiple organs] and time from diagnosis of metastatic disease [ vs ≥18 months]) to receive oral regorafenib 160 mg once daily or placebo on days 1–21 of each 28 day cycle; patients in both groups were also to receive best supportive care. Participants, investigators, and the study funder were masked to treatment assignment. The primary endpoint was overall survival, and we analysed data on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT01584830. Findings Between April 29, 2012, and Feb 6, 2013, we screened 243 patients and randomly assigned 204 patients to receive either regorafenib (136 [67%]) or placebo (68 [33%]). After a median follow-up of 7·4 months (IQR 4·3–12·2), overall survival was significantly better with regorafenib than it was with placebo (hazard ratio 0·55, 95% CI 0·40–0·77, one-sided p=0·00016; median overall survival 8·8 months [95% CI 7·3–9·8] in the regorafenib group vs 6·3 months [4·8–7·6] in the placebo group). Drug-related adverse events occurred in 132 (97%) of 136 regorafenib recipients and 31 (46%) of 68 placebo recipients. The most frequent grade 3 or higher regorafenib-related adverse events were hand–foot skin reaction (22 [16%] of 136 patients in the regorafenib group vs none in the placebo group), hypertension (15 [11%] vs two [3%] of 68 patients in the placebo group), hyperbilirubinaemia (nine [7%] vs one [1%]), hypophosphataemia (nine [7%] vs none), alanine aminotransferase concentration increases (nine [7%] vs none), aspartate aminotransferase concentration increases (eight [6%] vs none), lipase concentration increases (six [4%] vs one [1%]), and maculopapular rash (six [4%] vs none). Drug-related serious adverse events occurred in 12 (9%) patients in the regorafenib group and three (4%) in the placebo group. Interpretation This phase 3 trial is the second to show an overall survival benefit with regorafenib compared with placebo in patients with treatment-refractory metastatic colorectal cancer, substantiating the role of regorafenib as an important treatment option for patients whose disease has progressed after standard treatments. In this trial, preceding standard treatments did not necessarily include targeted treatments. Adverse events were generally consistent with the known safety profile of regorafenib in this setting. Funding Bayer HealthCare Pharmaceuticals.